Covetrus Announces Changes to Senior Management Team
7.1.2020 16:00:00 EET | Business Wire | Press release
Covetrus™ (NASDAQ: CVET), a global leader in animal-health technology and services, today announced several changes to its senior management and regional leadership teams.
Effective January 7, 2020, Mike Ellis has been promoted to executive vice president and will add North America to his existing responsibilities as the leader of Europe. David Hinton has been promoted to executive vice president and will add global sourcing to his existing responsibilities as the leader of APAC & Emerging Markets. Georgia Wraight has been promoted to executive vice president and will continue to lead Covetrus’ Global Technology Solutions organization, which was formed in November 2019 following the combination of the company’s Global Software Services and Global Prescription Management business units. Matthew Leonard will transition into an advisory role and depart as the company’s global supply chain officer and executive vice president and president, North America.
In addition to these senior management team changes, the company is also introducing a new organizational framework in Europe that centralizes the larger regions into three geographic groupings – Northern Europe, Central Europe and Central Eastern Europe – to simplify operations to better meet the needs of customers and manufacturer partners.
- Northern Europe, which includes the United Kingdom, Ireland and France, will be led by Jamie Tattersfield, vice president, Northern Europe. Jamie most recently served as the managing director of Covetrus United Kingdom and has had roles within the U.K. veterinary supplies business, including at legacy W. & J. Dunlop Ltd. (“Dunlops), for more than 30 years.
- Central Europe, which includes Germany, Switzerland, Austria, Netherlands and Belgium, will be led by Thomas Friedl, vice president, Central Europe. Thomas most recently served as the managing director of Covetrus’ DACH region and has had a number of roles of increased responsibility in the animal health and medical device industries over the last 25 years.
- Central Eastern Europe, which includes Poland, Czech Republic, Slovakia and Romania, will be led by Karolina Brodziak, vice president, Central Eastern Europe. Karolina most recently served as the managing director of Covetrus Poland and has had a number of roles within the company’s Polish distribution business of animal health products and services, including at Medivet, for approximately 20 years.
The vice president of each geographic grouping as well as the managing director of Covetrus’ Spain and Portugal business will report to Mike Ellis.
Covetrus is also announcing the hiring of Simon Hellams, effective February 12, 2020, to serve as vice president and managing director, Australia and New Zealand (ANZ). Simon has had a number of successful leadership positions over the last two decades in both the animal health and agribusiness sectors in the ANZ region, including for Ruralco Holdings, Boehringer Ingleheim and Merial. Simon will report to David Hinton.
About Covetrus
Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We’re bringing together products, services and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine, with more than 5,500 employees, serving over 100,000 customers around the globe. Learn more at covetrus.com.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our future financial and operating results including 2019 guidance, and other matters. We may, in some cases use terms such as "predicts," "believes," "potential," "continue," "anticipates," "estimates," "expects," "plans," "intends," "may," "could," "might," "likely," "will," "should" or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous risks and uncertainties, including but not limited to, risks associated with our management transition; the ability to successfully integrate operations and employees; the ability to realize anticipated benefits and synergies of the transactions that created Covetrus; the potential impact of the consummation of the transactions on relationships, including with employees, customers and competitors; the ability to retain key personnel; the ability to achieve performance targets; changes in financial markets, interest rates and foreign currency exchange rates; changes in our market; the impact of litigation; the impact of Brexit; and those additional risks and factors discussed, including those discussed under the heading "Risk Factors" in our Annual Report on Form 10-K filed on March 29, 2019 and Quarterly Report on Form 10-Q filed for the quarter ended September 30, 2019, and in our other SEC filings. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005347/en/
Contact information
Nicholas Jansen, Investor Relations
nicholas.jansen@covetrus.com
| (207) 550-8106
Kiní Schoop, Public Relations
kini.schoop@covetrus.com
| (207)550-8018
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives European Union Approval for Restylane ® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping11.8.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810880899/en/ The lower face plays a pivotal role in overall facial balance, influencing proportions and profile.2 This region is an increasing area of concern for patients, with around one in four people expressing concerns related to lower face sagging and chin shape.5 When asked about their facial priorities, a third of people pointed out issues with their chin shape – a key contributor to facial definition and structural harmony.5 Genetic factors and age-related changes can lead to reduced chin d
Stonebranch is Again Named a Leader in the 2026 Gartner ® Magic Quadrant ™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 18:00:00 EEST | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build, manage, and optimize automation at enterprise scale.” Stonebranch UAC helps organizations unify, manage, and scale automation ac
Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 17:09:00 EEST | Press release
Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboration, and help deliver mission-ready capabilities faster. “Bringing Frontgrade’s capabilities to Huntsville is a meaningful milestone for me, both personally and professionally. For decades, this
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 16:00:00 EEST | Press release
Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized authority on applied AI, she is a Gartner-recognized thought leader and author on AI SaaS and product en
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical collaboration will explore potential targeted combination approaches for patients with RAS-addicted cancers Potential drug combinations for development as part of the clinical collaboration will include certain BeOne assets and Revolution Medicines’ four clinical RAS(ON) inhibitors: daraxonrasib, a RAS(ON) multi-selective inhibitor; zo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
